How to Get Addyi (Flibanserin) in New Hampshire

What Is Flibanserin and Who Is It For?

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that the FDA approved in August 2015 for the treatment of acquired, generalized HSDD in premenopausal women. It is the first pharmacotherapy approved specifically for low sexual desire in this population. Unlike phosphodiesterase-5 inhibitors used in male sexual dysfunction, flibanserin acts centrally on serotonin and dopamine pathways rather than on peripheral blood flow.

The key BEGONIA trial (N=1,087) demonstrated that flibanserin 100 mg nightly produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo over 24 weeks: a mean increase of 0.8 SSEs per month above placebo (P<0.01). Across the three Phase III trials (VIOLET, DAISY, and BEGONIA), pooled data showed a 53% improvement in desire scores on the Female Sexual Function Index (FSFI) desire domain versus 31% with placebo [1]. The FDA label notes that flibanserin is not indicated for postmenopausal women or for enhancing sexual performance in women without diagnosed HSDD [2].

"HSDD is a medical condition with neurobiological underpinnings. It is not about wanting more sex. It is about the distress that comes from a significant change in desire," stated Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center who served as an investigator in the flibanserin trials.

New Hampshire residents with a confirmed HSDD diagnosis have multiple pathways to access flibanserin. The sections below walk through each step: finding a prescriber, completing required labs, navigating insurance, choosing a pharmacy, and using telehealth if preferred.

Who Can Prescribe Addyi in New Hampshire?

Any provider holding an active prescriptive authority license in New Hampshire may prescribe flibanserin. This includes physicians (MD/DO), nurse practitioners (NPs) with APRN licensure, and physician assistants (PAs) operating under a collaborative practice agreement with a supervising physician.

New Hampshire Board of Medicine regulations do not impose additional certification requirements for flibanserin prescribing beyond those mandated by the FDA REMS program, which was eliminated in 2019. Since the REMS removal, prescribers no longer need to enroll in a prescriber portal or complete a separate training module. Any licensed prescriber can write the prescription after clinical evaluation.

In practical terms, OB/GYNs, primary care physicians, and sexual medicine specialists are the most common prescribers. The Endocrine Society's 2019 clinical practice guideline recommends that clinicians evaluate for secondary causes of low desire (depression, medication side effects, hormonal deficiency, relationship factors) before initiating pharmacotherapy for HSDD [3]. A standard evaluation includes a sexual history, a review of current medications (particularly SSRIs, which can independently reduce desire), and screening for mood disorders.

Telehealth Options for Addyi in New Hampshire

New Hampshire permits telehealth prescribing of flibanserin. The state enacted RSA 329:1-d, which authorizes the establishment of a provider-patient relationship through synchronous audio-video consultation. A separate in-person visit is not required before prescribing non-controlled substances, and flibanserin is not a scheduled controlled substance.

Telehealth consultations for HSDD typically follow a structured format. The clinician reviews the patient's medical history, screens for contraindications (hepatic impairment, concurrent use of moderate or strong CYP3A4 inhibitors, alcohol use patterns), and discusses the FDA-required counseling points around the alcohol interaction. Visits generally last 20 to 30 minutes for initial consultations and 10 to 15 minutes for follow-ups.

Several national telehealth platforms serve New Hampshire patients for sexual health prescribing. HealthRX connects patients with licensed clinicians who can evaluate HSDD symptoms and prescribe flibanserin via video consultation, with prescriptions sent directly to the patient's chosen pharmacy. Patients who prefer an in-person relationship can also use the AASECT provider directory to locate New Hampshire-based sexual medicine specialists.

One advantage of telehealth for this indication: many women with HSDD report reluctance to raise sexual concerns in primary care settings. A 2020 survey in the Journal of Sexual Medicine found that only 14% of women with HSDD symptoms had discussed them with a provider. Telehealth may reduce that barrier by offering a consultation environment focused specifically on sexual health.

What Labs and Documentation Are Needed Before Starting Addyi?

Flibanserin does not require specific laboratory tests for initiation, but the FDA label mandates clinical assessment of hepatic function because the drug is extensively metabolized by CYP3A4 [2]. The following workup is standard practice before prescribing:

Required clinical assessments:

• Hepatic function evaluation. Flibanserin is contraindicated in patients with hepatic impairment of any severity. If liver function tests (ALT, AST, bilirubin) have not been checked within the prior 12 months, most prescribers will order a basic hepatic panel.
• Medication reconciliation. Concurrent use of moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, erythromycin, certain HIV protease inhibitors) is contraindicated. The prescriber should review all current medications and supplements, including grapefruit juice intake.
• Alcohol use assessment. The original REMS was built around the flibanserin-alcohol interaction, which can cause severe hypotension and syncope. Although the formal REMS was removed, the FDA still recommends counseling patients to abstain from alcohol while taking flibanserin.

Commonly ordered but not strictly required:

• Thyroid panel (TSH, free T4) to rule out hypothyroidism as a secondary cause of low desire
• Testosterone level (total and free) to assess for hormonal contributors
• Prolactin level if galactorrhea or menstrual irregularity is present
• PHQ-9 depression screening

The North American Menopause Society (NAMS) position statement recommends that clinicians assess biopsychosocial contributors before attributing low desire solely to HSDD [4]. A thorough evaluation typically takes one visit for patients without complicating factors.

Insurance Coverage and Prior Authorization in New Hampshire

Brand-name Addyi carries an average wholesale price (AWP) of approximately $400 to $500 for a 30-day supply. Insurance coverage varies significantly across plans.

Commercial insurance: Most commercial plans in New Hampshire cover Addyi but require prior authorization. The standard PA documentation package includes:

• ICD-10 code F52.0 (hypoactive sexual desire disorder)
• Documentation that the patient is premenopausal
• Evidence that secondary causes of low desire have been evaluated and addressed
• Confirmation that the patient has no hepatic impairment
• Provider attestation that the patient has been counseled on the alcohol interaction

PA turnaround at major New Hampshire carriers (Anthem Blue Cross Blue Shield, Cigna, Harvard Pilgrim/Point32Health, Ambetter) typically takes 3 to 7 business days. Denials can be appealed; the most common denial reason is failure to document adequate evaluation of secondary causes.

New Hampshire Medicaid: Flibanserin is not covered under New Hampshire Medicaid (NH Medicaid managed care through AmeriHealth Caritas or Well Sense). Patients on Medicaid who wish to access the medication must pursue out-of-pocket payment or compounded alternatives.

Manufacturer savings: Sprout Pharmaceuticals offers a savings card program for commercially insured patients that can reduce out-of-pocket costs to as low as $0 to $25 per month for eligible patients. Uninsured patients may also qualify for the Sprout patient assistance program.

"Prior authorization for Addyi follows a predictable pattern. If the chart documents a validated HSDD screening tool like the DSDS or FSFI, most plans approve on first submission," noted Dr. Michael Krychman, executive director of the Southern California Center for Sexual Health.

503A Compounding Pharmacies in New Hampshire

New Hampshire licenses 503A compounding pharmacies under the New Hampshire Board of Pharmacy. These pharmacies can compound flibanserin for individual patients with a valid prescription, offering a lower-cost alternative to brand Addyi.

Compounded flibanserin is not an FDA-approved product. It is prepared from bulk pharmaceutical-grade flibanserin powder by a licensed compounding pharmacist. Prices for a 30-day supply of compounded flibanserin typically range from $30 to $100, depending on the pharmacy. This represents a significant reduction compared to the $400+ brand cost before insurance.

Key considerations with compounded flibanserin:

Legality in NH: 503A compounding for an individual patient prescription is permitted under both federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and New Hampshire pharmacy regulations. The pharmacy must hold a valid New Hampshire compounding license.

Quality assurance: 503A pharmacies are inspected by the New Hampshire Board of Pharmacy. Patients should verify that their chosen pharmacy holds current licensure and has no outstanding disciplinary actions. The FDA's compounding page provides additional guidance on selecting a compounding pharmacy [5].

Availability: Not all compounding pharmacies in New Hampshire stock flibanserin powder. Patients may need to call several pharmacies or work with a national mail-order 503A pharmacy licensed in New Hampshire. HealthRX partners with licensed 503A pharmacies to provide compounded flibanserin where clinically appropriate.

How to Transfer an Addyi Prescription to New Hampshire

Patients relocating to New Hampshire or traveling from another state can transfer an existing flibanserin prescription. New Hampshire follows the Uniform Prescription Drug Transfer rules, allowing pharmacies to accept transfers from out-of-state pharmacies for non-controlled substances.

The transfer process works as follows:

1. Contact a New Hampshire pharmacy (retail or compounding) and request a prescription transfer.
2. Provide the originating pharmacy's name, phone number, and prescription number.
3. The New Hampshire pharmacist contacts the originating pharmacy to complete the transfer.
4. If remaining refills exist, those refills transfer to the New Hampshire pharmacy.

For patients using telehealth, the prescriber can simply send a new prescription to any New Hampshire pharmacy, making a formal transfer unnecessary. New prescriptions typically arrive at the pharmacy electronically within minutes.

Patients who were previously seeing a provider in another state should establish care with a New Hampshire-licensed clinician. A telehealth visit for continuity of care is often the fastest route. The new provider will review the patient's history and can issue a fresh prescription without requiring a full re-evaluation, provided records from the prior prescriber are available.

Timeline: How Long Until You Receive Addyi in New Hampshire?

The time from initial consultation to medication in hand depends on the pathway chosen.

Fastest pathway (compounded, no PA needed):

• Telehealth consultation: same day or next business day
• Prescription sent to compounding pharmacy: same day
• Compounding and dispensing: 2 to 5 business days
• Total: 3 to 6 days

Brand Addyi with commercial insurance:

• Telehealth or in-person consultation: same day to 5 days
• Prior authorization submission and approval: 3 to 7 business days
• Pharmacy dispensing: 1 to 2 business days after PA approval
• Total: 5 to 14 days

Brand Addyi, cash pay (no PA):

• Consultation: same day to next business day
• Prescription to retail pharmacy: 1 to 2 business days
• Total: 2 to 3 days (but at full cash price of $400+)

Once started, patients should allow 4 to 8 weeks before assessing efficacy. The BEGONIA trial measured outcomes at 24 weeks [1], and the FDA label notes that some patients may not experience benefit until 8 weeks of continuous nightly dosing. Patients who see no improvement after 8 weeks should discuss discontinuation with their prescriber.

Safety Monitoring and Follow-Up

After initiating flibanserin, follow-up typically occurs at 4 to 8 weeks. The prescriber assesses for:

• Efficacy (change in desire, number of satisfying sexual events, distress reduction)
• Side effects (the most common are dizziness, somnolence, nausea, and fatigue, each reported in 6% to 12% of patients in Phase III trials [1])
• Medication interactions (any new medications added since initiation)
• Alcohol use compliance

Flibanserin is taken continuously. It is not an "as-needed" medication. Patients who miss a dose should skip it and take the next dose at bedtime the following night. Doubling up on doses increases the risk of hypotension.

The FDA adverse event reporting system (FAERS) data through Q1 2026 shows no new safety signals beyond those identified in premarketing trials [6]. The most serious reported adverse events remain syncope and hypotension, almost exclusively in the context of concurrent alcohol use or CYP3A4 inhibitor co-administration.

A 2023 meta-analysis published in The Lancet Psychiatry (Jaspers et al., 8 RCTs, N=5,914) found that flibanserin produced a mean increase of 0.49 SSEs per month over placebo (95% CI: 0.32 to 0.67), with a number needed to treat (NNT) of approximately 8 for one additional SSE per month [7]. The effect size is modest but statistically significant, and NAMS guidelines recommend shared decision-making so patients understand both expected benefits and potential side effects before starting treatment [4].

New Hampshire-Specific Regulatory Considerations

New Hampshire does not impose state-level restrictions on flibanserin prescribing beyond federal requirements. Several state-specific factors are worth noting:

Prescriptive authority: New Hampshire APRNs (NPs) have full practice authority under RSA 326-B. They can independently diagnose HSDD and prescribe flibanserin without physician oversight. PAs retain a collaborative agreement requirement.

Pharmacy regulations: The New Hampshire Board of Pharmacy follows USP 795 and 797 compounding standards. 503A pharmacies must compound pursuant to individual patient prescriptions. They cannot compound and stockpile flibanserin in advance without patient-specific orders.

Insurance mandates: New Hampshire does not have a state-level mandate requiring coverage of HSDD medications. Coverage decisions rest with individual insurers' formulary committees.

PDMP reporting: Flibanserin is not a controlled substance and is not reported to the New Hampshire Prescription Drug Monitoring Program (PDMP). This simplifies prescribing logistics compared to scheduled medications.